Company Information
- Type:
- Company
- Country:
- United States of America
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 24 November 2008 Letter of Commitment Letter of Re-commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Financial Information
Non-Financial Information
Communication On Progress
| Published On | Title | Level/Status |
|---|---|---|
| 29-Jul-2024 | 2024 Communication on Progress | Submitted |
| 03-Oct-2022 | PerkinElmer's 2021 Communication on Progress | Active |
| 14-Nov-2012 | Communication on Progress | Active |
| 14-Nov-2011 | 2011 Communication on Progress | Active |
| 22-Nov-2010 | 2010 Communication on Progress | Not applicable |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note: We can redact your name, signature and any other personal information from your CoP. However, in alignment with our standard procedure, please note that we do not delete the online profile of a former participant, nor its letters of commitment and/or any other documents (including CoPs) that have been submitted voluntarily by participants as part of their engagement with our initiative. Transparency and disclosure are core values to which participants adhere when joining the UN Global Compact, and we continue to uphold these values by ensuring a transparent record of our current and past participants on our public database. Please see our CoP Removal Request Policy for more information.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. Starting with the 2022 Early Adopter Programme, there will no longer be any differentiation levels.